Biohaven is a modern pharmaceutical company that is guided by science and inspired to change the lives of people with unmet medical needs.
New Haven, CT
Joined April 2018
- Tweets1.2K
- Following848
- Followers2.2K
- Likes3.4K
#NEWS: The @US_FDA has accepted our resubmitted NDA for review of our investigational #SCA treatment and plans to convene an Advisory Committee. This milestone reflects our commitment to the SCA community and people living with this devastating disease.
#DaysMatter
We’re joining the oncology community at #ESMO26 to share new research from Biohaven. Visit our poster to learn more about the science driving our work in oncology.
#CancerResearch #DaysMatter
ALT Biohaven at the ESMO Congress 2026
We’re headed to @ASNKidney Kidney Week! Visit Biohaven at Booth #791 to learn more about our research in IgAN. Also, at #KidneyWk, we’ll present preclinical research on our investigational TRAP™ degrader in membranous nephropathy.
#DaysMatter
ALT 2026 American Society of Nephrology Kidney Week
How should we approach ADA response characterization as biotherapeutics become increasingly complex? Our Executive Director of Bioanalytical Sciences will explore domain specificity, historical recommendations and future perspectives at the Immunogenicity & Bioassay Summit.
ALT Johanna Mora, Ph.D. - speaker at Immunogenicity & Bioassay Summit.
Exciting progress from our oncology pipeline: clinical data on our investigational FGFR3-directed ADC have been selected for oral presentation at #ENA2026! We look forward to sharing findings from the ongoing Phase 1 study in Barcelona this November.
brnw.ch/21x6aZb
New approaches in oncology are expanding to explore how every component of a medicine can work together to improve precision, durability and therapeutic potential.
#DaysMatter
#Oncology
#CancerResearch
#DrugDevelopment
We’re looking forward to the conversations at this year’s ABI Sweden Conference! Our Chief Translational Officer will moderate a panel bringing together industry leaders to discuss the next generation of autoimmune medicines.
#DaysMatter
#ABI26
ALT ABI Conference
The Biohaven team is headed to Athens and looking forward to sharing new research through both an oral presentation and a poster presentation at the @IlaeWeb European Epilepsy Congress.
#EEC2026
#DaysMatter
#Epilepsy
#Neurology
ALT International League Against Epilepsy Europe, Epilepsy Congress
Today, we announced a strategic global licensing and collaboration agreement with SK Biopharmaceuticals, the parent company of @SKLifeScience, focused on advancing our Kv7 platform and opakalim, our lead candidate in development for focal epilepsy.
Read the full announcement: bit.ly/4hQAU5i
In her latest LinkedIn article, our Executive Director of Clinical Operations at Biohaven, reflects on more than two decades in drug development and the lessons she's learned about resilience, collaboration and trusting the scientific process.
Read more: brnw.ch/21x4wiC
At #ESMO2026, our team will present new data from our investigational BHV-1530 program, highlighting our continued commitment to advancing innovative approaches in oncology. We look forward to sharing our latest research with the global cancer community. brnw.ch/21x4j3X
ALT Biohaven to present new clinical data at ESMO
We’re pleased to share that our Executive Vice President and Head of Drug Discovery will host a workshop at the Autoimmune Neuromuscular and Nerve Disorders Drug Development Summit next week in Boston. Learn more: bit.ly/4vtGKh0
#DaysMatter
What excites investigators about BHV-1300? Innovation and the potential to advance Graves’ disease treatment with a targeted, mechanism-based approach. Learn more about our Graves' disease clinical trial: brnw.ch/21x3JKc
#DaysMatter
In the news: @Neurology_Live featured our Chief Medical Officer discussing the latest data from our investigational epilepsy program and the ongoing need for new treatment options. Read the full feature below.
brnw.ch/21x3zMr
#DaysMatter
#Epilepsy
Biohaven retweeted
What sets opakalim apart from earlier Kv7 therapies? No off-target GABA potentiation, and that may be the key to its cleaner CNS tolerability profile.
@biohaven CMO Irfan Qureshi, MD breaks it down in a new Q&A🔬👇
neurologylive.com/view/irfan…
It was great connecting with the nephrology community at the @ERAkidney Congress in Glasgow.
Thank you to everyone who stopped by our booth to learn more about our TRAP™ degrader and shared meaningful conversations with our team. See you next year!
#ERA26
ALT ERA Congress in Glasgow, Scotland
Our Chief Translational Officer will be speaking at the @GoldmanSachs Annual Global Healthcare Conference, sharing insights on our pipeline developments.
#DaysMatter
#Innovation
#Pipeline
We’re excited to be part of the important conversations happening in metabolic health at @ADA_DiabetesPro. These discussions are critical to advance a deeper understanding of the complexity of obesity, and to drive scientific progress forward.
#ADASciSessions
#MedEd
Our annual Research & Development Day brought together our leadership team, industry experts and investors to share the latest on Biohaven’s pipeline progress in immunology, epilepsy, obesity and more. View the presentation here: brnw.ch/21x344H
#DaysMatter
#Investors
ALT Biohaven’s R&D Day
Biohaven is heading to the @ERAkidney Congress with a booth highlighting our TRAP™ degrader. Come stop by, say hello to our team and learn more about our work in kidney disease: brnw.ch/21x324Y
#ERA26
#DaysMatter
#IgAN
#KidneyDisease
#MedEd
ALT ERA Congress